Protein kinases provide an attractive target in treating childhood sarcoma due to the ‘druggable’ nature of the molecules and the striking success of tyrosine kinase inhibitors in other malignancies such as chronic myeloid leukaemia (CML) or gastrointestinal stromal tumours (GIST) [159]. This evidence concerns the gene WEE1 and sarcoma.